Study Registry

There is no translation available.

Taking part in a clinical trial can be a good choice but it is often hard to find a clinical trial that is right for you. Many patient organisations and websites maintain lists of clinical trials. The following table lists some of the clinical trials available worldwide. Please note: this is not an exhaustive list, so please check with your local patient organisation. Other trials may be available in your country. If you are aware of an open trial that should be listed here, please send us the trial information to: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!

 

GIST trials

Trial Name Subtype Results Agents Phase Status Sponsor
SSG XXII: 3 vs. 5 years of adjuvant imatinib Operable GIST Not available yet Imatinib III Open, recruiting Scandinavian Sarcoma Group (SSG)
REGISTRI KIT/PDGFR wild type GIST Not available yet Regorafenib II Open, recruiting Grupo Espanol de Investigacion en Sarcomas
Voyager Unresectable or metastatic GIST Not available yet Avapritinib vs. regorafenib III Closed, active Blueprint Medicines Corporation
Crenolanib GIST (D842V mutation) Not available yet Crenolanib vs. placebo in D842V mutated GIST III Closed, active Arog Pharmaceuticals, Inc.
INTRIGUE GIST Not available yet DCC-2618 (ripretinib) vs. sunitinib III Closed, active Deciphera Pharmaceuticals LLC
INVICTUS GIST, all types of KIT and PDGFRa mutations Further information see here DCC-2618 vs. placebo III Closed, active Deciphera Pharmaceuticals LLC

 

Sarcoma trials

Trial Name Subtype Results Agents Phase Status Sponsor
STRASS2 Leiomyosarcoma & Liposarcoma Not available yet Preoperative chemotherapy & surgery III Open, recruiting EORTC
REGOBONE Ewing's sarcoma, Chondrosarcomas, Osteosarcomas, Chondromas Not available yet Regorafenib vs. placebo II Open, recruiting (France only) UNICANCER
Cabozantinib in HGUtS High Grade Uterine Sarcoma Not availalble yet Cabozantinib II Open, recruiting EORTC
rEECur Ewing's sarcoma Not available yet Four different chemotherapy regimens II/III Open, recruiting University of Birmingham
Euro Ewing 2012 Ewing's sarcoma Not available yet Different chemotherapy regimens III Open, recruiting University of Birmingham

Spearhead 1

Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Not available yet Gene therapy: ADP-A2M4 II Open, recruiting Adaptimmune
ANITA Soft Tissue Sarcoma Not available yet Nintedanib with Ifosfamide in advanced, metastatic Soft Tissue Sarcoma II Closed, active EORTC in collaboration with Boehringer Ingelheim
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY) Myxoid Liposarcoma Not available yet Preoperative Radiotherapy II Closed, active The Netherlands Cancer Center
Selinexor in Advanced Liposarcoma (SEAL) Dedifferentiated Liposarcoma Phase II results available Selinexor II/III Closed, active Karyopharm Therapeutics

 

Desmoid tumours / Aggressive fibromatosis trials

Trial Name Subtype Results Agents Phase Status Sponsor
RINGSIDE Progressing Desmoid Tumors Not availalble yet AL 102 vs. placebo II/III Open, recruting Ayala Pharmaceuticals, Inc.
Nirogacestat in Desmoid Tumor/Aggressive Fibromatosis Desmoid Tumor/Aggressive Fibromatosis Not availalble yet Nirogacestat III Closed, active SpringWorks Therapeutics, Inc.
 
The Desmoid Tumour Research Foundation has a extensive list of further ongoing, mostly mono-country clinical trials for patients with desmoid tumour / aggressive fibromatosis. Please find it here.

Chordoma trials

The Chordoma Foundation has a extensive list of clinical trials designed specifically for chordoma patients, as well as other relevant trials recommended by the Chordoma Foundation’s MAB on their website. Please see for the clinical trials list here

Expanded access programms

An Expanded Access Program (EAP) allows physicians and patients access to pre-approval, investigational drugs outside of the clinical trial setting. An EAP can also be called a Managed Access Program (MAP), Early Access Program, or Compassionate Use Program (CUP).